相关实验视频
Updated: Jun 16, 2025

06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
826
血小板聚合对循环氧化酶抑制和使用阻抗聚合计的血小板聚合反应和血素受体对抗:试点研究
Auni C Williams1, Kat G Fisher1, Lacy M Alexander1,2
1Noll Laboratory, Department of Kinesiology, The Pennsylvania State University, University Park, Pennsylvania, USA.
Physiological reports
|August 20, 2024
概括
阻抗聚合计在全血中提供可重复的血小板功能分析. 阿司匹林和特鲁干预证实了其测量循环氧基因酶和血栓素受体活性的能力.
科学领域:
- 血液学 血液学 血液学
- 临床化学 临床化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 光传导聚合计是血小板功能分析的标准方法.
- 全血分析比基于等离子体的方法具有优势.
- 阻抗聚合计为评估血小板聚合提供了一种替代方法.
研究的目的:
- 为了评估阻抗聚合计的可重复性,用于血小板功能测试.
- 评估阿司匹林 (循环氧基酶抑制) 对血小板聚合反应的影响.
- 为了确定特鲁特罗班 (血小板素受体对抗剂) 对酸诱导的血小板聚合的影响.
主要方法:
- 从11名参与者那里收集了静脉血液样本,在至少两周的时间内,在三个时间点进行了采集.
- 使用原蛋白 (1微克/毫升和5微克/毫升) 和酸 (50毫米) 诱导了血小板聚合.
- 干预包括7天的阿司匹林 (每天81毫克) 或对照期,以及用terutroban或盐水进行ex vivo化.
主要成果:
- 阻抗聚合计证明了1μg/mL原诱导聚合的高测试内和测试间可重复性.
- 阿司匹林显著减弱了对原 (两种度) 和酸的聚合反应.
- 特鲁特罗班显著减弱了对阿拉基酸的聚合反应.
结论:
- 阻抗聚合计显示了对纵向血小板功能研究的足够可重复性,特别是在1μg/mL原蛋白.
- 该方法可以可靠地检测阿司匹林和特鲁的作用,支持其用于研究血小板功能和新陈代谢.
- 由于测试间重复性较低,5μg/mL的原蛋白和阿拉基酸可能最适合单个时间点的机制研究.
相关概念视频
Formation of the Platelet Plug
5.4K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
5.4K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
501
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
501

